Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)

Capsule summary Long-term disease control is challenging for patients with psoriasis. Current topical treatment follows a reactive approach to disease relapse.Long-term proactive management with calcipotriene/betamethasone dipropionate foam twice-weekly was more efficacious versus vehicle foam for prolonging time to first relapse, increasing time in remission and reducing number of relapses.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research